FindTrial
Sign In

SGN-35

DRUG3 trials

Sponsors

Seagen Inc., M.D. Anderson Cancer Center

Conditions

CD-30 Positive Anaplastic Large T-cell Cutaneous LymphomaCutaneous LymphomasDisease, HodgkinHematologic DisorderLymphomaLymphoma, Large-Cell, AnaplasticLymphoma, Non-HodgkinLymphoma, Primary Cutaneous Anaplastic Large Cell

Phase 1

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
CompletedNCT00430846
Seagen Inc.Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Start: 2006-11-30End: 2009-07-31Updated: 2014-12-18
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
TerminatedNCT00649584
Seagen Inc.Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Start: 2008-03-31End: 2010-02-28Updated: 2014-12-18

Phase 2

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Active, not recruitingNCT01352520
M.D. Anderson Cancer CenterCD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Cutaneous Lymphomas, Hematologic Disorder +5
Start: 2011-06-01End: 2028-01-31Updated: 2026-07-16

Related Papers

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens
The Journal of Clinical Pharmacology2020-06-2810 citations
Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.
Journal of Clinical Oncology2019-05-2012 citations
Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis
JAMA Dermatology2017-10-0435 citations
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
2010-11-01932 citations